Results 181 to 190 of about 158,698 (267)

The Spleen and Anaemia [PDF]

BMJ, 1963
openaire   +2 more sources

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort. [PDF]

Lupus Sci Med
Hulej G, Arru F, Bianchi B, Bortoluzzi A, Brussino L, Castrignanò P, Cauli A, Cavagna L, Chessa E, Chiara E, De Angelis R, De Marchi G, Depascale R, Di Carlo M, Emmi G, Galvagni I, Gasparotto M, Gatto M, Gerli R, Govoni M, Lo Gullo A, Nano A, Negrini S, Noviello S, Orsolini G, Pazzola G, Piga M, Quartuccio L, Rossini M, Salvarani C, Silvagni E, Silvestri E, Tamussin M, Tizian M, Tomietto P, Urban ML, Vacca A, Vesentini F, Bracalenti M, Ramonda R, Doria A, Iaccarino L, Zen M.   +42 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Metabolic Syndrome With Concomitant Anaemia Among Patients With Type 2 Diabetes Mellitus in the Volta Region of Ghana: A Cross-Sectional Study. [PDF]

J Nutr Metab
Lokpo SY, Avoyi D, Boateng E, Ametepe S, Ussher FA, Appiah M, Kwadzokpui PK, Adejumo EN, Obirikorang C, Osei-Yeboah J, Ablordey K, Ibrahim A.   +11 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Effectiveness of anaemia interventions in indigenous populations across the globe: a systematic review protocol. [PDF]

BMJ Open
Thatoju PK, Mallya SD, Dhyani VS, Shetty RS, Kotebagilu NP, Pattanshetty SM, Bhat RG, Kunder MA, Kumar A, Kaur H, Poobalan A.   +10 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Elusive Gastric Atrophy in Children: Diagnostic Pitfalls and a Stepwise Approach. [PDF]

Case Rep Pediatr
Rodenbach N, Venter A, Rodriguez-Herrera A, Duder J, Lee E.   +4 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source